MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+3.74%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$644M
AUM Growth
+$644M
(+3.5%)
Cap. Flow
+$93.3M
Cap. Flow
% of AUM
14.5%
Top 10 Holdings %
Top 10 Hldgs %
53.54%
Holding
47
New
9
Increased
25
Reduced
4
Closed
3
Top Buys
| 1 |
Mirum Pharmaceuticals
MIRM
|
$16.8M |
| 2 |
Guardant Health
GH
|
$14.4M |
| 3 |
Alkermes
ALKS
|
$13.4M |
| 4 |
Lantheus
LNTH
|
$12M |
| 5 |
HilleVax
HLVX
|
$9.33M |
Top Sells
| 1 |
Geron
GERN
|
$34.6M |
| 2 |
Viridian Therapeutics
VRDN
|
$10.8M |
| 3 |
Amicus Therapeutics
FOLD
|
$8.47M |
| 4 |
Sutro Biopharma
STRO
|
$3.09M |
| 5 |
Viking Therapeutics
VKTX
|
$1.65M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$445M
| $133M | 20.73% | 7,648,268 | – | – |
|
2
Insmed
INSM
$28.8B
| $41.2M | 6.41% | 615,391 +84,597 | +16% | +$5.67M |
|
3
Olema Pharmaceuticals
OLMA
$375M
| $28.7M | 4.46% | 2,654,867 +701,177 | +36% | +$7.59M |
|
4
iTeos Therapeutics
ITOS
| $25.9M | 4.03% | 1,745,943 | – | – |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $25M | 3.88% | 557,184 +76,596 | +16% | +$3.43M |
|
6
Madrigal Pharmaceuticals
MDGL
$9.76B
| $19.9M | 3.1% | 71,185 +9,786 | +16% | +$2.74M |
|
7
Iovance Biotherapeutics
IOVA
$807M
| $19M | 2.95% | 2,366,714 +166,714 | +8% | +$1.34M |
|
8
Natera
NTRA
$23.1B
| $18.9M | 2.94% | 174,811 +2,398 | +1% | +$260K |
|
|
9
Mirum Pharmaceuticals
MIRM
$3.71B
| $16.8M | 2.62% | +492,569 | New | +$16.8M |
|
10
Ultragenyx Pharmaceutical
RARE
$2.89B
| $15.6M | 2.43% | 380,552 +134,962 | +55% | +$5.55M |
|
11
MoonLake Immunotherapeutics
MLTX
$3.54B
| $15.1M | 2.35% | 343,235 +47,185 | +16% | +$2.07M |
|
|
12
Guardant Health
GH
$8.41B
| $14.4M | 2.24% | +500,000 | New | +$14.4M |
|
13
Disc Medicine
IRON
$2.07B
| $13.8M | 2.14% | 305,658 +194,879 | +176% | +$8.78M |
|
|
14
Alkermes
ALKS
$4.78B
| $13.4M | 2.09% | +557,556 | New | +$13.4M |
|
15
Edgewise Therapeutics
EWTX
$1.51B
| $13.3M | 2.07% | 740,661 +299,402 | +68% | +$5.39M |
|
16
ALX Oncology
ALXO
$62.7M
| $13.2M | 2.04% | 2,180,864 +912,393 | +72% | +$5.5M |
|
|
MORF
17
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $12.6M | 1.96% | 369,384 +44,051 | +14% | +$1.5M |
|
|
18
Lantheus
LNTH
$3.73B
| $12M | 1.87% | +150,000 | New | +$12M |
|
19
Revolution Medicines
RVMD
$7.1B
| $11.2M | 1.75% | 289,396 +16,179 | +6% | +$628K |
|
|
AVDL
20
Avadel Pharmaceuticals
AVDL
$1.43B
| $11M | 1.71% | 783,242 -87,907 | -10% | -$1.24M |
|
21
Xeris Biopharma Holdings
XERS
$1.26B
| $10.9M | 1.69% | 4,830,526 +664,030 | +16% | +$1.49M |
|
22
Axsome Therapeutics
AXSM
$6.05B
| $10.7M | 1.66% | 132,312 +18,185 | +16% | +$1.46M |
|
23
KalVista Pharmaceuticals
KALV
$678M
| $10.4M | 1.61% | 881,937 +121,215 | +16% | +$1.43M |
|
24
Intellia Therapeutics
NTLA
$1.22B
| $9.93M | 1.54% | 443,503 +10,905 | +3% | +$244K |
|
|
25
HilleVax
HLVX
$105M
| $9.33M | 1.45% | +645,085 | New | +$9.33M |
|